Amendments to the specification:

Please delete the paragraph beginning on line 21 page 6 and ending on line 26 page 7 and replace with the following:

In a further aspect of the invention there is provided a process for preparing compounds of formula (I), or a pharmaceutically acceptable derivative thereof, which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)

wherein Z^1, Z^2, Z^3, Z^4 and Z^5, m, n, R^1, R^2, R^3 and R^4 are as defined in formula (I), and X and Y may be the following combinations:

(i) X is M and Y is $CH_2CO_2R^X$

(ii) X is CO_2R^Y and Y is $CH_2CO_2R^X$

(iii) one of X and Y is $CH{=}SPh_2$ and the other is CHO

(iv) X is CH_3 and Y is CHO

(v) X is CH_3 and Y is CO_2R^X

(vi) X is $CH_2CO_2R^Y$ and Y is CO_2R^X

(vii) X is $CH{=}PR^Z{}_3$ and Y is CHO

(viii) X is CHO and Y is $CH{=}PR^Z{}_3$

(ix) X is halogen and Y is $CH{=}CH_2$

(x) one of X and Y is COW and the other is $NHR^{11'}$ ~~or NCO~~

(xi) one of X and Y is $(CH_2)_p$-V and the other is $(CH_2)_qNHR^{11'}$, $(CH_2)_qOH$, $(CH_2)_qSH$ or $(CH_2)_qSCOR^X$ where p+q=1

(xii) one of X and Y is CHO and the other is $NHR^{11'}$

(xiii) one of X and Y is OH and the other is $-CH{=}N_2$

in which V and W are leaving groups, R^X and R^Y are (C_{1-6})alkyl and R^Z is aryl or (C_{1-6})alkyl;

or

(b) reacting a compound of formula (IV) with a compound of formula (Vb):



(IV)



(Vb)

wherein Z^1, Z^2, Z^3, Z^4 and Z^5, m, n, R^1, R^2, R^3 and R^4 are as defined in formula (I), X is $CH_2NHR^{11'}$ and Y is CHO or COW or X is CH_2OH and Y is $-CH=N_2$;

in which $R^{11'}$, $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are R^{11}, R^1, R^2, R^3 and R^4 or groups convertible thereto, and thereafter optionally or as necessary converting $R^{11'}$, $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ to $R^{11'}$, R^1, R^2, R^3 and R^4, converting A-B to other A-B, interconverting R^{11}, R^1, R^2, R^3 and/or R^4 and forming a pharmaceutically acceptable derivative thereof.

Please delete the paragraph beginning on line 29 page 3 and ending on line 36 page 3 and replace with the following:

When R^1 is substituted alkoxy it is preferably C_{2-6} alkoxy substitituted by optionally N-substituted amino, guanidino or amidino, more preferably by amino, or C_{1-6}alkoxy substituted by piperidyl. Suitable examples of R^1 alkoxy include methoxy, n-propyloxy, i-butyloxy, aminoethyloxy, aminopropyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4-ylmethyloxy, ~~phthalimido pentyloxy~~ or 2-aminocarbonylprop-2-oxy. ~~Preferably R^1 is in the 6-position on the quinoline nucleus.~~ Preferably R^1 is methoxy, amino(C_{3-5})alkyloxy, nitro or fluoro, most preferably methoxy.

Please delete the title compound name for Example 7 starting on page 26, line 27 and ending on page 27, line 28 and replace with the following:

Example 7. [3R,4S]-1-Heptyl-4-N-(6-methoxy-1,5-naphthyridin-4-yl)-3-(1-(R/S)- 2-dihydroxyethyl)-piperidineacetamide oxalate

Please add the priority information paragraph to the specification by inserting the following new paragraph before the first line of the specification:

This application is a continuation of U.S. application serial no. 09/807,275 filed April 11, 2001 which is a 371 of PCT/GB99/03366, filed October 11, 1999.

An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Please insert the attached abstract, following the claims.